Media

28 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to announce that it has entered into a research collaboration with the University of Oxford’s Structural Genomics Consortium department (“SGC-Oxford”).

28 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to announce its preliminary results for the year ended 31 July 2015.

Wednesday, 07 October 2015

Research update

Small molecule leads against IL-17 for inflammation and autoimmune diseases

7 October, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to provide the following research update on key, highly selective small molecule leads in its programme against Interleukin-17 (IL-17), a critical and high value target in inflammation and autoimmune diseases.

Wednesday, 23 September 2015

Research update

Breakthrough compounds for diabetes and inflammation

23 September, 2015 – C4X Discovery Holdings plc (“C4XD”), a leader in rational drug discovery and design, is pleased to provide the following research update on recent key milestones in its programmes for Type 2 diabetes and inflammation, two areas of significant unmet medical need that represent large pharmaceutical markets.

3 September, 2015 – C4X Discovery Holdings plc (“C4XD” or “the Company”), a leader in rational drug discovery and design, today announced that it is further strengthening its team with two new management appointments.

Rapid progression demonstrates power of C4XD technology

20 May, 2015 – C4X Discovery Holdings plc ("C4XD" or "the Company"), a leader in rational drug discovery and design, today announced that it has selected a drug candidate from its Orexin-1 programme to enter pre-clinical development prior to the initiation of clinical studies for the treatment of stress-related addictive disorders. This represents a major milestone for C4XD.

Manchester and London, UK, 27 April, 2015 – C4X Discovery Holdings plc (AIM: C4XD), a leader in the rational discovery design and optimisation of novel small molecule therapeutics, today announces its interim unaudited results for the six months ended 31 January 2015.

Manchester and London, UK, 30 March, 2015 – C4X Discovery (AIM: C4XD), a leader in rational drug discovery and design, today announced that it has won a further grant from the UK's innovation agency, Innovate UK. This Smart award is the second Innovate UK grant C4XD has won recently in the area of type 2 diabetes, following our success with the Biomedical Catalyst, announced in July 2014.